Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
Roberta FrapolliEzia BelloMarianna PonzoIlaria CraparottaLaura MannarinoSara BallabioSergio MarchiniLaura CarrassaPaolo UbezioLuca PorcuSilvia BrichRoberta SanfilippoPaolo Giovanni CasaliAlessandro GronchiSilvana PilottiMaurizio D'IncalciPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The finding that the combination of pioglitazone and trabectedin induces terminal adipocytic differentiation of some MLSs with the complete pathologic response and cure of tumor-bearing mice provides a strong rationale to test the combination of trabectedin and pioglitazone in patients with MLS.